Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 6/2017

01-04-2017 | Leading Article

Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy

Authors: Darren Wong, David van Duin

Published in: Drugs | Issue 6/2017

Login to get access

Abstract

Carbapenem-resistant Enterobacteriaceae are amongst the most feared pathogens due to severely limited treatment options. In response to this threat, three novel β-lactamase inhibitors have been developed in an attempt to reinvigorate and sustain our current antimicrobial therapies. Avibactam, vaborbactam, and relebactam are inhibitor agents with high affinity to Ambler class A and C β-lactamases and favorable outcomes in current clinical trials. However, although they do possess key similarities, these agents have unique differences which may have important clinical implications. The microbiologic spectrum, pharmacokinetics, and key clinical trials for each of these novel agents are reviewed. A proposed role in therapy and potential novel combinations are examined.
Literature
1.
Öztürk H, Ozkirimli E, Özgür A. Classification of Beta-lactamases and penicillin binding proteins using ligand-centric network models. PLoS One. 2015;10(2):e0117874.CrossRefPubMedPubMedCentral
2.
Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969–76.CrossRefPubMed
3.
Bonomo RA. Beta-Lactamases: a focus on current challenges. Cold Spring Harb Perspect Med. 2017;7(1):a025239.
4.
Drawz SM, Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835–46.CrossRefPubMedPubMedCentral
5.
van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2016;1–10.
6.
Wong D, Spellberg B. Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant enterobacteriaceae. Virulence. 2016;1–8.
7.
Stachyra T, Péchereau MC, Bruneau JM, Claudon M, Frère JM, Miossec C, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132–8.CrossRefPubMedPubMedCentral
8.
Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, et al. Ceftazidime–avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159–77.CrossRefPubMed
9.
van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–41.CrossRefPubMed
10.
de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime–avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012–2014). Antimicrob Agents Chemother. 2016;60(5):3163–9.CrossRefPubMedPubMedCentral
11.
Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390–4.CrossRefPubMed
12.
Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother. 2015;59(7):3710–7.CrossRefPubMedPubMedCentral
13.
Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–8.CrossRefPubMed
14.
Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3). pii: e02097-16.
15.
Sader HS, Huband MD, Castanheira M, Flamm RK. Antimicrobial susceptibility of Pseudomonas aeruginosa: results from four years (2012–2015) of the International Network for Optimal Resistance Monitoring (INFORM) Program in the United States. Antimicrob Agents Chemother. 2017;61(3). pii: e02252-16.
16.
Citron DM, Tyrrell KL, Merriam V, Goldstein EJ. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 2011;55(7):3616–20.CrossRefPubMedPubMedCentral
17.
Merdjan H, Tarral A, Das S, Li J. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211–8.CrossRefPubMed
18.
Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70(10):2862–9.CrossRefPubMed
19.
Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921–31.CrossRefPubMed
20.
Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68(5):1183–92.CrossRefPubMed
21.
Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime–avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016;63(6):754–62.CrossRefPubMedPubMedCentral
22.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380–9.CrossRefPubMedPubMedCentral
23.
Food and Drug Administration. Briefing Package NDA 206494 ceftazidime–avibactam. 2014; pp. 1–55.
24.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime–avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–73.CrossRefPubMed
25.
King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant enterobacteriaceae (CRE) infections: a multi-center study. Open Forum Infect Dis. 2016;3(Supplement 1):2047.
26.
Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682–92.CrossRefPubMed
27.
Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454–8.CrossRefPubMedPubMedCentral
28.
Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2013;68(8):1825–31.CrossRefPubMed
29.
Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856–60.CrossRefPubMedPubMedCentral
30.
Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother. 2013;57(6):2620–30.CrossRefPubMedPubMedCentral
31.
Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59(12):7232–9.CrossRefPubMedPubMedCentral
32.
Griffith D, Loutit J, Morgan E, Durso S, Dudley M. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 in healthy adult subjects. 24th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain; 2014.
33.
Meanwell C, Loutit J, Dudley M. TANGO 1 Phase 3 trial results; conference call, PDF; 2016 June 27.
34.
35.
Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorg Med Chem Lett. 2014;24(3):780–5.CrossRefPubMed
36.
Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–31.CrossRefPubMedPubMedCentral
37.
Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012;56(7):3753–7.CrossRefPubMedPubMedCentral
38.
Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–90.PubMed
39.
Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992;36(9):2046–8.CrossRefPubMedPubMedCentral
40.
Snydman DR, Jacobus NV, McDermott L. In vitro evaluation of the activity of imipenem/relebactam (imipenem/mk-7655) against 451 recent clinical isolates of bacteroides group and related species. Antimicrob Agents Chemother. 2016;60(10):6393–7.CrossRefPubMed
41.
Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother. 2015;59(2):790–5.CrossRefPubMedPubMedCentral
42.
Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, et al. Phase 2, dose-ranging study of relebactam with imipenem/cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60(10):6234–43.CrossRefPubMed
43.
44.
45.
Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 1999;43(2):424–7.PubMedPubMedCentral
46.
Rodríguez-Martínez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(11):4783–8.CrossRefPubMedPubMedCentral
47.
Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol. 2012;302(2):63–8.CrossRefPubMed
48.
Hauck C, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, et al. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect. 2016;22(6):513–9.CrossRefPubMed
49.
Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, et al. High rates of nonsusceptibility to ceftazidime–avibactam and identification of new delhi metallo-β-lactamase production in enterobacteriaceae bloodstream infections at a major cancer center. Clin Infect Dis. 2016;63(7):954–8.CrossRefPubMed
50.
Goldstein EJ, Citron DM, Merriam CV, Tyrrell KL. Comparative in vitro activity of ceftaroline, ceftaroline–avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Diagn Microbiol Infect Dis. 2013;76(3):347–51.CrossRefPubMed
51.
Werth BJ, Rybak MJ. Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2014;58(1):559–62.CrossRefPubMedPubMedCentral
52.
Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, et al. Can ceftazidime/avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02243-16.
Metadata
Title
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy
Authors
Darren Wong
David van Duin
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 6/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0725-1

Other articles of this Issue 6/2017

Drugs 6/2017 Go to the issue

Therapy in Practice

Options for Treating Pain in Cancer Patients with Dysphagia

AdisInsight Report

Baricitinib: First Global Approval

Review Article

Pediatric Osteoporosis: Diagnosis and Treatment Considerations

Review Article

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects

Leading Article

Triazole Resistance in Aspergillus Species: An Emerging Problem

AdisInsight Report

Sarilumab: First Global Approval